Valuation: Genomma Lab Internacional, S.A.B. de C.V.

Market Cap 12.98B 702M 631M 589M 534M 1B 66.78B 1.01B 7.07B 2.76B 34.66B 2.63B 2.58B 111B P/E 2026 *
7.03x
P/E 2027 * 6.74x
Enterprise Value 17.17B 928M 835M 779M 706M 1.33B 88.34B 1.33B 9.35B 3.65B 45.85B 3.49B 3.41B 147B EV / Sales 2026 *
0.95x
EV / Sales 2027 * 0.89x
Free-Float
68.95%
Yield 2026 *
6.01%
Yield 2027 * 8.05%
1 day+1.68%
1 week+3.50%
Current month+5.89%
1 month+5.30%
3 months-12.03%
6 months-29.28%
Current year-25.60%
1 week 12.7
Extreme 12.7
13.4
1 month 12.22
Extreme 12.22
13.4
Current year 12.22
Extreme 12.22
19.48
1 year 12.22
Extreme 12.22
19.48
3 years 12.22
Extreme 12.22
29.18
5 years 12.22
Extreme 12.22
29.18
10 years 11.1
Extreme 11.1
29.18
Manager TitleAgeSince
Chief Executive Officer - 12/04/2023
Director of Finance/CFO - 01/12/2015
Investor Relations Contact - 01/10/2019
Director TitleAgeSince
Chairman - 30/10/1996
Director/Board Member - 06/07/2010
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.68%+3.50%-23.11%+0.76% 707M
+3.62%+4.43%+47.52%+98.41% 1,040B
+2.13%-0.34%+33.01%+61.88% 599B
+3.32%+6.30%+23.09%+91.59% 485B
+3.80%+3.83%+71.96%+41.69% 350B
+3.09%+6.03%+27.85%+45.42% 345B
+2.82%+4.68%+17.38%+40.15% 272B
+3.40%+2.86%-3.33%+12.08% 244B
+3.21%+5.84%+45.73%+49.99% 223B
+3.80%+6.45%+29.89%+97.73% 183B
Average +3.08%+2.52%+27.00%+53.97% 374.35B
Weighted average by Cap. +3.38%+2.31%+36.01%+68.67%

Financials

2026 *2027 *
Net sales 17.99B 973M 875M 816M 740M 1.39B 92.57B 1.4B 9.8B 3.82B 48.05B 3.65B 3.57B 155B 18.74B 1.01B 911M 850M 771M 1.45B 96.43B 1.46B 10.2B 3.98B 50.05B 3.8B 3.72B 161B
Net income 1.91B 103M 92.66M 86.47M 78.37M 147M 9.81B 148M 1.04B 405M 5.09B 387M 379M 16.37B 2.06B 111M 100M 93.37M 84.62M 159M 10.59B 160M 1.12B 438M 5.5B 418M 409M 17.68B
Net Debt 4.19B 227M 204M 190M 172M 323M 21.56B 325M 2.28B 891M 11.19B 851M 832M 35.99B 3.67B 198M 178M 166M 151M 283M 18.86B 285M 2B 779M 9.79B 744M 728M 31.48B
Projected Income Statement - Annual - Genomma Lab Internacional, S.A.B. de C.V.
Logo Genomma Lab Internacional, S.A.B. de C.V.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
Employees
1,658
Date Price Change Volume
14/10/26 MXN 13.79 +3.61% 5,368,486
13/10/26 MXN 13.31 +1.68% 5,635,182
12/10/26 MXN 13.09 +0.38% 3,424,687
09/10/26 MXN 13.04 +1.95% 4,311,051
08/10/26 MXN 12.79 -0.23% 3,747,298
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Genomma Lab Internacional, S.A.B. de C.V.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
13.31MXN
Average target price
21.67MXN
Spread / Average Target
+62.78%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Genomma Lab Internacional, S.A.B. de C.V.
  1. Stock Market
  2. Stocks
  3. LAB B Stock